{"id":"W4415900074","doi":"10.1016/s2352-3026(25)00264-9","title":"Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study","year":2025,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Phase (matter); Clinical trial; Phases of clinical research; MEDLINE","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001626433,0.001066856,0.002023057,0.0003305533,0.0002605176,0.0009567665,0.0005778623,0.001362698,0.004621522],"category_scores_gemma":[0.0009898833,0.0004779921,0.001785542,0.0002922988,0.0009062181,0.001040446,0.0003340202,0.002157631,0.0006050135],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005425707,"about_ca_system_score_gemma":0.0006217959,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001042419,"about_ca_topic_score_gemma":0.001859458,"domain_scores_codex":[0.9995767,0.0002214973,0.00002133114,0.00006364405,0.0000345621,0.00008219634],"domain_scores_gemma":[0.9993914,0.0001990307,0.0001066464,0.00004568631,0.00002478493,0.0002323678],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9653817,0.004605505,0.0007746324,0.0005453519,0.001236906,0.00007456234,0.00007986025,0.0003679922,0.005062899,0.0001274099,0.0005477534,0.02119533],"study_design_scores_gemma":[0.9364705,0.05915357,0.00260765,0.00003297251,0.0004079088,0.00005863384,0.00002671003,0.0002523062,0.000346461,0.0001159931,0.0005135799,0.00001379589],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9913049,0.004967713,0.0005478414,0.0003433739,0.0001965141,0.0009567079,0.0004561406,0.00006795798,0.001158925],"genre_scores_gemma":[0.9906495,0.003310162,0.001068396,0.0008453645,0.0002450862,0.0008992081,0.0007324796,0.00001831822,0.002231504],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004621522,"threshold_uncertainty_score":0.01546055,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05743628741329941,"score_gpt":0.4161781471176606,"score_spread":0.3587418597043612,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}